The study of the Cys-loop receptor's role in neuroimmune interactions of glioblastoma multiforme

The project team investigates the role of Cys-loop receptors (nicotinic acetylcholine, glycine and gamma-aminobutyric acid receptors) in the formation and functioning of synaptic contacts between glioma tumour cells and neurons. Earlier in the literature, an increased expression of genes encoding ionotropic glutamate receptors, nicotinic acetylcholine, ionotropic and metabotropic gamma-aminobutyric acid receptors, as well as transporters and synthetase enzymes corresponding to the receptors of these neurotransmitters, was shown in glioma cells involved in the formation of synapses. There is also a fairly extensive body of works devoted to the role of nicotinic acetylcholine receptors in glioma cells. However, the specific role of representatives of the superfamily of Cys-loop receptors (nicotinic acetylcholine, glycine, and gamma-aminobutyric acid receptors) in the synapses of neurons with tumour cells remains poorly understood, and the signalling cascades triggered by these receptors in tumour cells are unknown. Simultaneously, establishing the relationship of individual subtypes of cis-loop receptors with cellular structures and molecular signalling pathways in gliomas will lay the foundation for the creation of drugs and diagnostic tools for the effective treatment of some types of these diseases.

July 1, 2021 — June 30, 2024

Kudryavtsev D.S. (PI), Antipova N.V. (Co-PI), Ivanov I.A. (Co-PI), Shelukhina I.V. (Co-PI)

Department of molecular bases of neurosignalization, Laboratory of molecular toxinology, Laboratory of ligand-receptor interactions, Laboratory of membrane bioenergetics

Grant, RSF, 18000000 rub.

List of publications

  1. Kasheverov I, Kudryavtsev D, Shelukhina I, Nikolaev G, Utkin Y, Tsetlin V (2022). Marine Origin Ligands of Nicotinic Receptors: Low Molecular Compounds, Peptides and Proteins for Fundamental Research and Practical Applications. Biomolecules 12 (2), 189
  2. Yagolovich AV, Isakova AA, Artykov AA, Vorontsova YV, Mazur DV, Antipova NV, Pavlyukov MS, Shakhparonov MI, Gileva AM, Markvicheva EA, Plotnikova EA, Pankratov AA, Kirpichnikov MP, Gasparian ME, Dolgikh DA (2022). DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int J Mol Sci 23 (20),
  3. Levakov SA, Pertseva YA, Obukhova EA, Paukov SV, Bondarenko NL, Shakhparonov MI, Antipova NV (2023). Search for prognostic markers of the course of endometriosis. Akush Ginekol (Mosk) 2023 (2), 32–36
  4. Ivanov IA, Siniavin AE, Palikov VA, Senko DA, Shelukhina IV, Epifanova LA, Ojomoko LO, Belukhina SY, Prokopev NA, Landau MA, Palikova YA, Kazakov VA, Borozdina NA, Bervinova AV, Dyachenko IA, Kasheverov IE, Tsetlin VI, Kudryavtsev DS (2023). Analogs of 6-Bromohypaphorine with Increased Agonist Potency for α7 Nicotinic Receptor as Anti-Inflammatory Analgesic Agents. Mar Drugs 21 (6), 368
  5. Gondarenko E, Mazur D, Masliakova M, Ryabukha Y, Kasheverov I, Utkin Y, Tsetlin V, Shahparonov M, Kudryavtsev D, Antipova N (2024). Subtype-Selective Peptide and Protein Neurotoxic Inhibitors of Nicotinic Acetylcholine Receptors Enhance Proliferation of Patient-Derived Glioblastoma Cell Lines. Toxins (Basel) 16 (2), 80
  6. Levakov SA, Pertseva YA, Kaviladze MG, Gromova TA, Chernyshenko TA, Gondarenko EA, Mazur DV, Mishanova AV, Shakhparonov MI, Mashtagova KM, Antipova NV (2023). Evaluation of expression patterns of different nicotinic acetylcholine receptor subunits in ovarian endometriosis in the search for promising new therapeutic targets for endometriosis. Voprosy Ginekologii, Akusherstva i Perinatologii 22 (5), 5–14